On August 3rd, 2023, GlaxoSmithKline Consumer Nigeria Plc (GLAXOSMITH) released a circular disclosing its decision to cease operations in Nigeria. The document outlined GSK UK Group’s plan to discontinue sales of prescription medicines and vaccines in Nigeria through the GSK local operating companies. In its stead, it intends to introduce a direct distribution model involving a local third-party, distributing GSK pharmaceutical product in the Nigerian market. It’s worth noting that GSK Group holds 46.42% of GlaxoSmithKline Consumer Nigeria Plc through Setfirst Limited (27.31%) and Smithkline Beecham Limited (19.11%), while the remaining 53.58% is owned by the investing public.
You May Also Like
Banking Sector Update – Taxing Times, Windfall Worries
- July 30, 2024
Dear All, Kindly find attached the report. Regards, Banking Sector Update – Taxing Times, Windfall Worries
Equity Note – TRANSCORP Shares Reconstruction
- May 15, 2024
Dear All, Kindly find attached the report. Regards, Equity Note – TRANSCORP Shares Reconstruction
FIDELITYBK Rights Issue Note
- July 1, 2024
Dear All, Kindly find attached the report. Regards, FIDELITYBK Rights Issue Note
Banking Sector Update Ecobank Nigeria Faces Capital Adequacy Hurdle
- September 24, 2024
Dear All, Kindly find attached the report. Regards, Banking Sector Update Ecobank Nigeria Faces Capital Adequacy Hurdle
FBNH Rights Issue Note – November 2024
- November 5, 2024
Dear All, Trust this meets you well. FBNH opened its Rights Issue Offer today with the intention to raise…